Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 2:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 105 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Shionogi Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

NCT04147715
View directory record Official record
Conditions
Healthy Volunteer
Interventions
S-648414, Placebo, Midazolam, Dolutegravir
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

NCT01993940
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy

NCT01240759
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
S-707106 Dose A, S-707106 Dose B, S-707106 Dose C, Placebo A tablet, Metformin
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

NCT00920426
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744 30mg, Placebo, GSK1265744 5mg
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Fort Lauderdale, Florida • Orlando, Florida • Vero Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults

NCT00708110
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1349572, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Bakersfield, California • Long Beach, California • Newport Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Sep 1, 2026, 2:13 PM EDT
Recruiting Phase 1Phase 2 Interventional

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

NCT05101070
View directory record Official record
Conditions
Solid Tumors
Interventions
S-531011, Pembrolizumab, Bevacizumab
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls

NCT07217886
View directory record Official record
Conditions
Renal Impairment
Interventions
S-892216-PO
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Orlando, Florida • St. Petersburg, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants

NCT06751017
View directory record Official record
Conditions
COVID-19
Interventions
S-892216, Carbamazepine
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

NCT01965158
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

NCT01443403
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Placebo, Naldemedine
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
49
States / cities
Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants

NCT05395104
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Midazolam, Cefiderocol
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

NCT01382238
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
Dolutegravir 50 mg tablet, Dolutegravir 50 mg oral granules
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2011 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Mass Balance Study

NCT00828763
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14c}-GSK1349572
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 4, 2009 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens

NCT03032380
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Meropenem, Linezolid
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
15
States / cities
New Haven, Connecticut • DeLand, Florida • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 2 Interventional

A Study of S-892216 in Participants With COVID-19

NCT06928051
View directory record Official record
Conditions
COVID-19
Interventions
S-892216, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 64 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
21
States / cities
Hot Springs, Arkansas • Coconut Creek, Florida • Coral Gables, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment

NCT06157242
View directory record Official record
Conditions
Bacterial Infections
Interventions
Xeruborbactam Oral Prodrug, Ceftibuten
Drug
Lead sponsor
Qpex Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects

NCT00788528
View directory record Official record
Conditions
Obesity
Interventions
S-2367 (velneperit)
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
766 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
73
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Healthy Volunteer Study To Assess The Bioavailability of GSK1265744 When Administered Orally Either When Fasted or Following a Meal.

NCT00812318
View directory record Official record
Conditions
HIV Infection, Infection, Human Immunodeficiency Virus
Interventions
GSK1265744 10 mg oral solution, GSK1265744 5 mg tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2012 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 2 Interventional

A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients

NCT00046332
View directory record Official record
Conditions
HIV Infections
Interventions
GW810781
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls

NCT07018492
View directory record Official record
Conditions
Hepatic Impairment
Interventions
BPN14770
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 1, 2026, 2:13 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

NCT04569084
View directory record Official record
Conditions
ALS
Interventions
MT-1186, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

NCT01214993
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Tuberculosis
Interventions
GSK1349572, Placebo, Iohexol Injection, Para-aminohippurate infusion
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 3 Interventional Results available

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT04577404
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
MT-1186
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Phoenix, Arizona • Rogers, Arkansas • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 1, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Food and Calcium on Pharmacokinetics of a Single Dose of S-888711 in Healthy Adult Volunteers

NCT03897413
View directory record Official record
Conditions
Healthy Volunteer
Interventions
S-888711, Calcium Antacid
Drug · Dietary Supplement
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2019 · Synced Sep 1, 2026, 2:13 PM EDT